- Home
- BTU vs VRNA Comparison
BTU vs VRNA Comparison
Compare BTU & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTU
- VRNA
- Stock Information
- Founded
- BTU 2016
- VRNA 2005
- Country
- BTU United States
- VRNA United Kingdom
- Employees
- BTU N/A
- VRNA N/A
- Industry
- BTU Coal Mining
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- BTU Energy
- VRNA Health Care
- Exchange
- BTU Nasdaq
- VRNA Nasdaq
- Market Cap
- BTU 2.8B
- VRNA 3.2B
- IPO Year
- BTU N/A
- VRNA 2017
- Fundamental
- Price
- BTU $20.64
- VRNA $42.02
- Analyst Decision
- BTU Strong Buy
- VRNA Strong Buy
- Analyst Count
- BTU 4
- VRNA 6
- Target Price
- BTU $29.00
- VRNA $43.83
- AVG Volume (30 Days)
- BTU 2.9M
- VRNA 938.4K
- Earning Date
- BTU 02-06-2025
- VRNA 11-04-2024
- Dividend Yield
- BTU 1.45%
- VRNA N/A
- EPS Growth
- BTU N/A
- VRNA N/A
- EPS
- BTU 3.78
- VRNA N/A
- Revenue
- BTU $4,348,600,000.00
- VRNA $5,624,000.00
- Revenue This Year
- BTU N/A
- VRNA N/A
- Revenue Next Year
- BTU N/A
- VRNA $644.06
- P/E Ratio
- BTU $5.42
- VRNA N/A
- Revenue Growth
- BTU N/A
- VRNA 1127.95
- 52 Week Low
- BTU $20.21
- VRNA $11.39
- 52 Week High
- BTU $29.94
- VRNA $43.73
- Technical
- Relative Strength Index (RSI)
- BTU 25.25
- VRNA 60.87
- Support Level
- BTU $20.95
- VRNA $39.67
- Resistance Level
- BTU $21.93
- VRNA $43.73
- Average True Range (ATR)
- BTU 0.72
- VRNA 1.72
- MACD
- BTU -0.14
- VRNA -0.01
- Stochastic Oscillator
- BTU 3.80
- VRNA 67.61
About BTU Peabody Energy Corporation
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. Powder River Basin segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan and other regions.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.